Hologic's Surgical business has been recording strong broad-based performance by expanding access to technologies into new ...

Hologic's strength in the molecular diagnostics wing instills optimism among investors. Yet, a dull macroeconomic environment raises concerns.

Raymond James lowered the firm’s price target on Hologic (HOLX) to $90 from $95 and keeps an Outperform rating on the shares. Hologic’s print was essentially in line, but revenue guidance was ...

Andrew Cooper; Analyst; Raymond James & Associates, Inc. Good afternoon and welcome to the Hologic's first quarter fiscal 2025 earnings conference call. My name is Lisa and I'm your operator for today ...

And welcome to the Hologic's First Quarter Fiscal 2025 Earnings ... to Genius and Breast Health to MyoSure and NovaSure and Surgical, we enjoy leading market shares that have proven durable ...

Hologic's Q1 2025 EPS exceeded expectations by $0.02. Revenue fell short by $8 million against forecasts. Stock price increased by 1.7% in after-hours trading. Full-year revenue guidance was lowered ...

Hologic's Q1 2025 EPS exceeded expectations by $0.02. Revenue fell short by $8 million against forecasts. Stock price increased by 1.7% in after-hours trading. Full-year revenue guidance was ...

MARLBOROUGH, Mass. (AP) — MARLBOROUGH, Mass. (AP) — Hologic Inc. (HOLX) on Wednesday reported fiscal first-quarter profit of $201 million. On a per-share basis, the Marlborough, Massachusetts ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 28, 2024. “Our financial results ...

Find out what happened in the markets today – and why you should care – with the free Daily Brief newsletter. Hologic's fiscal 2025 revenue outlook is under scrutiny after a decline in its breast ...